Recombinant infectious bursal disease virus carrying hepatitis C virus epitopes

Journal of Virology

Volumn 85, Issue 3, 2011, Pages 1408-1414

  Upadhyay, Chitra ^a   Ammayappan, Arun ^a   Patel, Deendayal ^c   Kovesdi, Imre ^b   Vakharia, Vikram N ^a  

^a UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE   (United States)

^b VectorLogics Inc   (United States)

^c HAUPTMAN WOODWARD MEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; COMPLEMENTARY DNA; EPITOPE; GLYCOPROTEIN E; NONSTRUCTURAL PROTEIN 5;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; GENE INSERTION; GENE SEQUENCE; GENETIC CODE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; INFECTIOUS BURSAL DISEASE VIRUS; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; VERO CELL; VIRUS CARRIER; VIRUS ENVELOPE; VIRUS GENOME; VIRUS NEUTRALIZATION; WESTERN BLOTTING;

ANIMALS; ANTIGENS, VIRAL; CELL LINE; CERCOPITHECUS AETHIOPS; DRUG CARRIERS; EPITOPES; GENETIC VECTORS; HEPACIVIRUS; HUMANS; INFECTIOUS BURSAL DISEASE VIRUS; IRIS DISEASES; MUTAGENESIS, INSERTIONAL; RECOMBINANT FUSION PROTEINS; SEQUENCE DELETION; VACCINES, SYNTHETIC; VIRAL HEPATITIS VACCINES;

HEPATITIS C VIRUS; INFECTIOUS BURSAL DISEASE VIRUS; MIRIDAE;

EID: 78651384505     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01391-10     Document Type: Article

References (31)

1. Bakacs, T., and J. N. Mehrishi. 2004. Examination of the value of treatment of decompensated viral hepatitis patients by intentionally coinfecting them with an apathogenic IBDV and using the lessons learnt to seriously consider treating patients infected with HIV using the apathogenic hepatitis G virus. Vaccine 23:3-13.
2. Bakacs, T., and J. N. Mehrishi. 2002. Intentional coinfection of patients with HCV infection using avian infection bursal disease virus. Hepatology 36:255.
3. Ben Abdeljelil, N., B. Delmas, and H. Mardassi. 2008. Replication and packaging of an infectious bursal disease virus segment A-derived minigenome. Virus Res. 136:146-151.
4. Birghan, C., E. Mundt, and A. E. Gorbalenya. 2000. A non-canonical Lon proteinase lacking the ATPase domain employs the Ser-Lys catalytic dyad to exercise broad control over the life cycle of a double-stranded RNA virus. EMBO J. 19:114-123.
5. Brizzard, B. L., R. G. Chubet, and D. L. Vizard. 1994. Immunoaffinity purification of FLAG epitope-tagged bacterial alkaline phosphatase using a novel monoclonal antibody and peptide elution. Biotechniques 16:730-735.
6. Caston, J. R., et al. 2001. C terminus of infectious bursal disease virus major capsid protein VP2 is involved in definition of the T number for capsid assembly. J. Virol. 75:10815-10828.
7. Coulibaly, F., et al. 2005. The birnavirus crystal structure reveals structural relationships among icosahedral viruses. Cell 120:761-772.
8. Csatary, L. K., R. Schnabel, and T. Bakacs. 1999. Successful treatment of decompensated chronic viral hepatitis by bursal disease virus vaccine. Anti-ancer Res. 19:629-633.
9. Csatary, L. K., L. Telegdy, P. Gergely, B. Bodey, and T. Bakacs. 1998. Preliminary report of a controlled trial of MTH-68/B virus vaccine treatment in acute B and C hepatitis: a phase II study. Anticancer Res. 18:1279-1282.
10. Da Costa, B., et al. 2002. The capsid of infectious bursal disease virus contains several small peptides arising from the maturation process of pVP2. J. Virol. 76:2393-2402. (Pubitemid 34150707)
11. Delmas, B., et al. 2004. Birnaviridae, p. 561-569. In C. M. Facquet, M. A. Mayo, J. Maniloff, U. Desselberger, and A. L. Ball (ed.), Virus taxonomy. Academic Press, London, United Kingdom.
12. Evan, G. I., G. K. Lewis, G. Ramsay, and J. M. Bishop. 1985. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol. Cell. Biol. 5:3610-3616.
13. Firbas, C., et al. 2006. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 24:4343-4353.
14. Garriga, D., et al. 2006. The 2.6-angstrom structure of infectious bursal disease virus-derived T 1 particles reveals new stabilizing elements of the virus capsid. J. Virol. 80:6895-6905.
15. Girard, M., A. Martin, and S. van der Werf. 1993. Potential use of poliovirus as a vector. Biologicals 21:371-377.
16. Jackwood, D. H., Y. M. Saif, and J. H. Hughes. 1987. Replication of infectious bursal disease virus in continuous cell lines. Avian Dis. 31:370-375.
17. Lee, C. C., et al. 2006. Crystal structure of infectious bursal disease virus VP2 subviral particle at 2.6A resolution: implications in virion assembly and immunogenicity. J. Struct. Biol. 155:74-86.
18. Mebatsion, T., et al. 2002. Newcastle disease virus (NDV) marker vaccine: an immunodominant epitope on the nucleoprotein gene of NDV can be deleted or replaced by a foreign epitope. J. Virol. 76:10138-10146.
19. Mundt, E., and V. N. Vakharia. 1996. Synthetic transcripts of doublestranded Birnavirus genome are infectious. Proc. Natl. Acad. Sci. U. S. A. 93:11131-11136.
20. Palese, P., F. Zavala, T. Muster, R. S. Nussenzweig, and A. Garcia-Sastre. 1997. Development of novel influenza virus vaccines and vectors. J. Infect. Dis. 176(Suppl. 1):S45-S49.
21. Pan, J., V. N. Vakharia, and Y. J. Tao. 2007. The structure of a birnavirus polymerase reveals a distinct active site topology. Proc. Natl. Acad. Sci. U. S. A. 104:7385-7390.
22. Park, M. J., J. H. Park, and H. M. Kwon. 2010. Mice as potential carriers of infectious bursal disease virus in chickens. Vet. J. 183:352-354.
23. Rémond, M., et al. 2009. Infectious bursal disease subviral particles displaying the foot-and-mouth disease virus major antigenic site. Vaccine 27:93-98.
24. Sanchez, A. B., and J. F. Rodriguez. 1999. Proteolytic processing in infectious bursal disease virus: identification of the polyprotein cleavage sites by site-irected mutagenesis. Virology 262:190-199.
25. Schödel, F. P. D., J. Hughes, R. Wirtz, and D. Milich. 1996. Hybrid hepatitis B virus core antigen as a vaccine carrier moiety. I. Presentation of foreign epitopes. J. Biotechnol. 44:91-96.
26. van den Berg, T. P., N. Eterradossi, D. Toquin, and G. Meulemans. 2000. Infectious bursal disease (Gumboro disease). Rev. Sci. Tech. 19:509-543.
27. von Einem, U. I., et al. 2004. VP1 of infectious bursal disease virus is an RNA-dependent RNA polymerase. J. Gen. Virol. 85:2221-2229.
28. Worgall, S., et al. 2005. Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid. J. Clin. Invest. 115:1281-1289.
29. Yao, K., M. A. Goodwin, and V. N. Vakharia. 1998. Generation of a mutant infectious bursal disease virus that does not cause bursal lesions. J. Virol. 72:2647-2654.
30. Yutani, S., et al. 2009. Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigenclass I-A alleles. Cancer Sci. 100:1935-1942.
31. Yutani, S., et al. 2007. Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy. Vaccine 25:7429-7435.